Ultimately, our study demonstrated that KMT2C/TP53 co‐mutation might be a potential biomarker to predict responses to PD‐1 blockade therapy in patients with NSCLC, and that adding KRAS to the biomarker combination might create a more robust parameter to identify the best responders to ICI therapy. Here, KRAS is linked to non-small cell lung carcinoma.